Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.No se pudo cargar la navegación global.
Synonyms
- Antistriated Muscle Antibodies
Special Instructions
This assay currently is not available in New York state.
|
This |
|
This assay currently is not available in New York state. |
Expected Turnaround Time
2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Storage Instructions
Maintain specimen at room temperature.
Stability Requirements
| Temperature | Period |
|---|---|
| Room temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
| Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Hemolyzed or lipemic serum
Test Details
Use
This test is recommended for differential evaluation of neuromuscular junction diseases including myasthenia gravis (MG).
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Immunofluorescence (IF)
Reference Interval
Negative: <1:100
Additional Information
Autoantibodies directed against the contractile elements of striated muscle are found in 30% of adult patients with myasthenia gravis and 80% of those with thymoma. These antibodies may also be detected in patients with: Lambert-Eaton myasthenic syndrome, small-cell lung carcinoma, breast carcinoma, patients treated with D-penicillamine, bone marrow transplant recipients having graft-versus-host disease, and autoimmune liver disorders.
References
Lanska DJ, “Diagnosis of Thymoma in Myasthenics Using Antistriated Muscle Antibodies: Predictive Value and Gain in Diagnostic Certainty,” Neurology, 1991, 41(4):520-4.2011250
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf